Market Research Logo

Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2018

Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2018 provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Metered Dose Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Metered Dose Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Metered Dose Inhaler Devices Overview
3 Products under Development
3.1 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
3.2 Metered Dose Inhaler Devices - Pipeline Products by Territory
3.3 Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Metered Dose Inhaler Devices - Ongoing Clinical Trials
4 Metered Dose Inhaler Devices - Pipeline Products under Development by Companies
4.1 Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
5 Metered Dose Inhaler Devices Companies and Product Overview
5.1 Aerophase Inc Company Overview
5.2 AstraZeneca Plc Company Overview
5.3 Bespak Europe Ltd Company Overview
5.4 Chiesi Farmaceutici SpA Company Overview
5.5 Circassia Pharmaceuticals Plc Company Overview
5.6 Globe Medical Tech Inc (Inactive) Company Overview
5.7 Lab Automate Technologies Inc Company Overview
5.8 Medicom Innovation Partner a/s Company Overview
5.9 Min USA LLC Company Overview
5.10 Pearl Therapeutics Inc Company Overview
5.11 Reciprocal Labs Corp Company Overview
5.12 Rensselaer Polytechnic Institute Company Overview
5.13 Vectura Group Plc Company Overview
5.14 Verona Pharma Plc Company Overview
6 Metered Dose Inhaler Devices- Recent Developments
6.1 Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director
6.2 May 22, 2018: Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies
6.3 May 17, 2018: New England Journal of Medicine Publishes two Trials for Symbicort as an Anti-inflammatory Reliever Therapy ‘as Needed’ in Mild Asthma
6.4 May 16, 2018: Novartis announces changes to the Executive Committee
6.5 May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
6.6 May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE
6.7 May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director
6.8 May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
6.9 May 01, 2018: Merck Announces First-Quarter 2018 Financial Results
6.10 Apr 26, 2018: Consort Medical: Director Declaration
6.11 Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
6.12 Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year
6.13 Apr 20, 2018: Vectura Announces Senior Management Change
6.14 Apr 20, 2018: Vectura Group: Directorate Change - Chief Financial Officer
6.15 Apr 20, 2018: Mylan Lays off around 500 Morgantown Employees
6.16 Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company
6.17 Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
6.18 Apr 11, 2018: Investor Day Highlights Durability of Mylan's Global Platform
6.19 Mar 21, 2018: Vectura Group: 2017 Preliminary Results
6.20 Mar 21, 2018: Vectura Group: 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products
6.21 Mar 20, 2018: Merck Names Jennifer Zachary As General Counsel
6.22 Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities
6.23 Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
6.24 Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM
6.25 Feb 12, 2018: AVITA Medical Announces FDA Approval Of Expansion Of RECELL Compassionate Use Program In Life Threatening Injuries
6.26 Feb 12, 2018: Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program
6.27 Feb 10, 2018: MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct A Clinical Trial With NanoTherm Therapy As Focal Ablation Treatment For Intermediate Risk Prostate Cancer
6.28 Feb 09, 2018: Novartis layoffs to start in April at closing Broomfield plant
6.29 Feb 08, 2018: Propeller Health Achieves ISO 13485 Medical Device Quality Certification
6.30 Jan 31, 2018: Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018.
6.31 Jan 29, 2018: Novartis India Appoints Jawed Zia As Vice Chairman And Managing Director
6.32 Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Table 2: Metered Dose Inhaler Devices - Pipeline Products by Territory
Table 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
Table 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
Table 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials
Table 6: Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development
Table 7: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Table 8: Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Metered Dose Inhaler - Product Status
Table 10: Metered Dose Inhaler - Product Description
Table 11: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Bevespi Aerosphere Inhalation Aerosol - Product Status
Table 13: Bevespi Aerosphere Inhalation Aerosol - Product Description
Table 14: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 15: VAL310 Easifill Valve - Product Status
Table 16: VAL310 Easifill Valve - Product Description
Table 17: Chiesi Farmaceutici SpA Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Trimbow - Product Status
Table 19: Trimbow - Product Description
Table 20: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Fliveo - Product Status
Table 22: Fliveo - Product Description
Table 23: Fluticasone propionate/Salmeterol xinafoate pMDI - Product Status
Table 24: Fluticasone propionate/Salmeterol xinafoate pMDI - Product Description
Table 25: Circassia Pharmaceuticals Plc - Ongoing Clinical Trials Overview
Table 26: Fluticasone propionate/Salmeterol xinafoate pMDI - A Phase III Registration Study of Seretide Substitute (PSX2005)
Table 27: Globe Medical Tech Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Inhaler - Product Status
Table 29: Inhaler - Product Description
Table 30: Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Ultrasonic Metered Dose Inhaler - Product Status
Table 32: Ultrasonic Metered Dose Inhaler - Product Description
Table 33: Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Asmair - Product Status
Table 35: Asmair - Product Description
Table 36: Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Envi - Product Status
Table 38: Envi - Product Description
Table 39: Pearl Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 40: PT001 - Product Status
Table 41: PT001 - Product Description
Table 42: PT010 - Product Status
Table 43: PT010 - Product Description
Table 44: Pearl Therapeutics Inc - Ongoing Clinical Trials Overview
Table 45: PT010 - A Randomized, Double-blind, Multi-center, Parallel-group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD: Ethos
Table 46: Reciprocal Labs Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 47: Connected Metered Dose Inhaler - Product Status
Table 48: Connected Metered Dose Inhaler - Product Description
Table 49: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Bloom Inhaler - Product Status
Table 51: Bloom Inhaler - Product Description
Table 52: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 53: Flutiform K-Haler - Product Status
Table 54: Flutiform K-Haler - Product Description
Table 55: Flutiform pMDI - Product Status
Table 56: Flutiform pMDI - Product Description
Table 57: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: RPL554 - Metered Dose Inhaler - Product Status
Table 59: RPL554 - Metered Dose Inhaler - Product Description
Table 60: Glossary
1.2 List of Figures
Figure 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Figure 2: Metered Dose Inhaler Devices - Pipeline Products by Territory
Figure 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
Figure 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
Figure 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report